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Abstract
The manifestation of coronary artery disease (CAD) follows a well-choreographed series of events that includes damage of
arterial endothelial cells and deposition of lipids in the sub-endothelial layers. Genome-wide association studies (GWAS) of
multiple populations with distinctive genetic and lifestyle backgrounds are a crucial step in understanding global CAD
pathophysiology. In this study, we report a GWAS on the genetic basis of arterial stenosis as measured by cardiac
catheterization in a Lebanese population. The locus of the phosphatase and actin regulator 1 gene (PHACTR1) showed
association with coronary stenosis in a discovery experiment with genome wide data in 1,949 individuals (rs9349379,
OR = 1.37, p = 1.5761025). The association was replicated in an additional 2,547 individuals (OR= 1.31, p = 8.8561026),
leading to genome-wide significant association in a combined analysis (OR = 1.34, p = 8.02610210). Results from this GWAS
support a central role of PHACTR1 in CAD susceptibility irrespective of lifestyle and ethnic divergences. This association
provides a plausible component for understanding molecular mechanisms involved in the formation of stenosis in cardiac
vessels and a potential drug target against CAD.
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Introduction
Heart disease is a leading cause of illness, disability and death in
industrialized countries, particularly in older people [1,2]. The
manifestation of CAD follows a well-choreographed series of
events that includes the damaging of endothelial cells of the
arteries and the gradual deposition of lipids in the sub-endothelial
layers [3,4]. CAD is a multifactorial disease, with both acquired
and inherited components implicated in its etiology [4]. While
most CAD risk factors can be ameliorated through lifestyle
changes, such as diet and exercise, inherited causes, i.e. genetic
make-up and family history of the disease, are not modifiable
[5–7]. A small proportion of CAD cases can be attributed to rare,
highly penetrant monogenic effects [8,9], whereas most cases
result from the cumulative effect of multiple susceptibility alleles
and environmental factors [5,10–13]. Indeed, recent GWAS have
identified common variants in several novel candidate genes for
cardiovascular disease, such as the CDKN2A/2B/ANRIL gene
cluster on 9p21.3, and PHACTR1 on chromosome 6p24.1 [14–
16]. However, differences in lifestyle can have major impact on
CAD risk and how these may influence the genetic association is
largely unknown.
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Replication of the GWAS results for the most significantly
associated polymorphisms in multiple populations with distinctive
genetic and lifestyle backgrounds may provide deeper understanding
of the pathophysiology of a multifactorial disease like CAD. The
current trend in GWA studies relies on genetic analyses of ever
increasingly large numbers of individuals, with meta-analysis of
cohorts that often are from different phenotypic, genetic and
environmental backgrounds as well as with diverse ascertainment
schemes [17–19]. A complementary approach lies in the use of smaller
but phenotypically well-characterized populations to probe genetic
determinants of CAD intermediary phenotypes. Such populations can
be especially informative when they have a specific genetic and
environment backgrounds. We have carried out investigations of a
genome-wide set of genetic variations associated with severity of CAD
measured by the degree of coronary stenosis in the Lebanese
population that displays limited admixture levels, specific genetic
background, and a generally Mediterranean diet and lifestyle. A study
has shown that twenty percent of the general Lebanese population has
high total cholesterol and LDL levels and that the prevalence of
overweight individuals in this population aged 20 years and above is
57.7% in men and 49.4% in women despite the healthy Mediterra-
nean diet consumed [20]. Further, it implicated several risk factors
including age, gender, hypertension, fasting blood glucose, lipoprotein
(a), and a positive family history of CAD as important predictors of
CAD in the Lebanese population. Since the majority of these factors
possess genetic determinants, it is of interest to conduct genome-wide
association studies and evaluate the association of gene polymorphisms
with CAD in this population and assess their contribution to the
disease development and prevention.
We carried out a discovery GWAS in 1,949 individuals with
coronary angiogram data followed by an independent replication
experiment in 2,547 subjects. We confirmed association with
common variants in PHACTR1 that were significantly associated
with this disease.
Materials and Methods
1. Study Subjects
The study subjects consisted of 4,741 individuals who under-
went cardiac catheterization following a single consistent and
stringent recruitment protocol between August, 2007 and June,
2009 at several hospitals in Lebanon [21]. Catheterization was
prompted for myocardial infarction (MI) (13.1%) as diagnosed by
electrocardiogram and high troponin levels, unstable angina
(30.3%), or other reasons, such as stable angina, or heart failure,
or reversible ischemia by stress testing (56.5%). All patients
underwent coronary catheterization by Judkins’ technique. The
four main coronary arteries: the left main artery (LMCA), the left
anterior descending artery (LAD), the left circumflex artery (LCx),
and the right coronary artery (RCA) were visualized from different
angles by angiography. Two experienced interventional cardiol-
ogists reviewed the coronary angiograms independently. The
stenotic lesions in these vessels were assessed and recorded as a
percentage of coronary blockage. The extent of the coronary
lesion was estimated visually by comparing the reduction in the
diameter of the narrowed vessel to a proximal assumed normal
arterial segment. Cardiologists performing the coronary angiog-
raphy collected a 20 mL blood sample from the arterial access site
of patients who provided a written consent for the whole study that
included blood collection and genetic analysis. Trained healthcare
professionals collected further data on the socio-demographic
background of all patients. Annotations were coded from medical
charts for additional data such as laboratory tests, prescribed
medications, and presence of other diseases and conditions.
Genomic DNA was extracted using a standard phenol extraction
procedure. The Institutional Review Board (IRB) at the Lebanese
American University approved the study protocol.
For the primary analysis, patients with a normal angiogram with
no visible lesions in any of the four coronary arteries were classified
as CAD category 1 and considered as control subjects. Patients with
coronary artery stenosis were classified into two categories: CAD
category 2 comprised patients with #50% stenosis (moderate) in
Table 1. Association of CAD stenosis categories with conventional risk factors.
GWA phase p value1) Replication phase p value1) Total p value1)
Stenosis level no mild severe no mild severe p value2) no mild severe
Total sample size n = 426 n = 216 n = 1307 n= 458 n = 414 n= 1675 n= 1076 n= 630 n = 2982
Gender (%) ,0.001 ,0.001 ,0.001 ,0.001
Female 184 (43.2) 76 (35.2) 273 (20.9) 232 (50.7) 173 (41.8) 444 (26.5) 416 (38.7) 249 (39.5) 717 (24.0)
Male 242 (56.8) 140 (64.8) 1034 (79.1) 226 (49.3) 240 (58.0) 1230 (73.4) 468 (43.5) 380 (60.3) 2264
(75.9)
Age (SD) 56.3 (11.7) 62.6 (11.4) 63.6 (10.8) ,0.001 56.1 (10.9 ) 60.2 (11.1 ) 63.2 (10.7 ),0.001 0.11 56.2 (11.3) 61.0 (11.3) 63.4
(10.7)
,0.001
History of type 2
Diabetes (%)
70 (16.4) 45 (20.8) 458 (35.0) ,0.001 84 (18.3) 101 (24.4) 610 (36.4) ,0.001 0.2 154 (14.3) 146 (23.2) 1068
(35.8)
,0.001
History of
Hypertension (%)
183 (43.0) 117 (54.2) 763 (58.4) ,0.001 250 (54.6) 261 (63.0) 1129 (67.4),0.001 ,0.001 433 (40.2) 378 (60.0) 1892
(63.4)
,0.001
History of
Hyperlipidemia
(%)
155 (36.4) 94 (43.5) 685 (52.4) ,0.001 178 (38.9) 190 (45.9) 882 (52.7) ,0.001 0.52 333 (30.9) 284 (45.1) 1567
(52.5)
,0.001
Family history
of CAD (%)
273 (64.1) 130 (60.2) 928 (71.0) ,0.001 187 (40.8) 166 (40.1) 711 (42.4) 0.626 ,0.001 460 (42.8) 296 (47.0) 1639
(55.0)
,0.001
Analysis was done in GWA (discovery) and replication phases separately and combined (total). No, mild, and severe correspond to CAD severity categories 1, 2 and 3.
1) p value indicating association of risk factors with CAD categories. 2) p value indicating association of risk factors with different phases. See Methods section for details.
doi:10.1371/journal.pone.0038663.t001
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any coronary artery, and CAD category 3 comprised patients with
.50% stenosis (severe) in any of the coronary arteries [22]. For the
genome-wide association analysis with CAD degree of stenosis, the
comparisons were done among subjects in each of the three CAD
categories. For the genome-wide association analysis with site of
stenosis for each of the 4 coronary arteries, patients in CAD
categories 1and 2 were compared to CAD category 3 patients.
2. Genotyping
2.1 Whole genome. For the initial discovery phase of the
study, DNA samples of the first 2,002 recruited individuals were
utilized for whole genome genotyping. A total of 1,210 and 792
individuals were genotyped by Illumina Human610-Quad Bead-
Chip and Illumina Human660W-Quad BeadChip respectively
(552 510 overlapping SNPs), as part of the Functional Genomic
Diagnostic Tools for Coronary Artery Disease project initiative
(FGENTCARD) [21]. Out of the 2,002 genomic DNA samples
genotyped, 1,949 non-duplicated samples with quality filtered
genotyping data were retained.
2.2 Targeted genotyping. For replication analyses, we have
selected (1) all SNPs with p-value ,1025 (n = 7) from primary
analysis (GWAS phase), (2) SNPs in previously identified candidate
genes that showed a p-value ,1023 (n = 8) in the GWAS phase
and (3) SNPs located in a region of 500 Kb around the eight
candidate genes (n = 5). These SNPs were re-genotyped by mass
spectrometry (Sequenom, CA) in the initial GWAS sample. In
addition, 2,739 independent replication samples from the same
ascertainment centers were genotyped by Sequenom mass
spectrometry. From the 2,739 genotyped samples, 192 individuals
were excluded due to missing clinical and demographic informa-
tion and the resulting 2,547 samples were analyzed. In addition to
the above 20 SNPs, rs12526453 in the PHACTR1 region that has
been previously identified to be associated with early-onset MI,
and not present on the Illumina chip for the GWAS phase, was
selected to be genotyped in the replication cohort.
3. Statistical Analysis
We characterized subjects using ordered (e.g. degree of stenosis)
and unordered (e.g. site of stenosis) categorical measures, and
continuous variables for analysis. The study was divided into an
initial discovery phase based on 1,949 individuals and 2,547
individuals for further genotyping to confirm genome-wide signals.
The associations of the CAD stenosis categories with conventional
risk factors were examined by Fisher’s exact test for count data,
and by ANOVA for continuous valued response variables. We also
evaluated the association of these risk factors between GWA and
replication phases. For every risk factor, we tested for differences in
proportion at each degree of stenosis between the two phases. A
one-degree of freedom log-linear analysis on the phase effect was
used for the qualitative traits, and two-way ANOVA for the
quantitative traits.
All SNPs with over 98% genotyping success rate, minor allele
frequency of above 1% and that are in Hardy-Weinberg
equilibrium (p.161027) were included in the analysis. All 20
SNPs selected were in HWE (p-value .1E-4) and had a MAF
more than or equal to 5%. The population substructure (ancestry
analysis) was examined by Principal Component Analysis (PCA)
using the EIGENSTRAT software [23].
Analyses were based on an additive genetic model. We
employed the cumulative logit analysis of the proportional odds
model [24] for CAD category data, which was expressed as ordinal
categorical data: no, mild and severe stenosis. Three covariates,
indicator of genotyping BeadChip, sex, and age at investigation of
coronary angiogram, were included in the model as a primary
analysis. P values were calculated by likelihood ratio test. A p-value
,5.061028 was considered to be genome-wide significant. The
replication set included the same categorical phenotype allowing
analysis with the same cumulative logit model. The results of the
discovery and replication phases were combined by fixed effect
meta-analysis using ‘‘rmeta’’ package in R.
Figure 1. Manhattan plot showing results of a GWA analysis in 1949 Lebanese patients for 513,079 SNPs. The Y-axis corresponds to the
significance of the association (-log10 p-values). The X-axis represents the physical location of the variant colored by chromosome.
doi:10.1371/journal.pone.0038663.g001
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Results
The study population has a mean age of 61.56 (611.33), 69.2%
of the individuals were males with a majority (73%) suffering from
.50% stenosis in at least one of the 4 main coronary arteries
(CAD category 3) (Table 1). CAD category 3 disease was
manifested in 78% of the diabetic subgroup. Similar patterns of
disease were observed in those suffering from hypertension,
hyperlipidemia or positive family history of CAD. As expected,
individuals with severe stenosis showed the highest frequency of
the traditional risk factors compared to patients with no or mild
stenosis. The results were statistically significant (Table 1).
1. GWAS Results
To map gene loci associated with coronary artery stenosis, SNPs
genotyped data in the discovery cohort of 1,949 individuals were
tested for association with stenosis category phenotypes. Of the
513,079 successfully genotyped SNPs that overlapped in the two
genotyping BeadChips, only one SNP, rs11186734 on chromo-
some 10, showed genome-wide significance (OR = 0.51,
p = 3.9461028) for association in the discovery cohort adjusted
for indicator of genotyping BeadChip, sex, and age at investigation
of coronary angiogram (Figure 1). The genomic control inflation
factor (l) [25], which compares observed association statistics
against the expected distribution was 1.033 suggesting no
systematic over-dispersion of the association statistics (Figure 2).
Furthermore, the incorporation of the first 10 components derived
from the PCA ancestry analysis as covariates into the association
did not affect the results appreciably. Other SNPs showing trend of
association were rs13006511 (OR = 0.61, p = 4.8861027) on
2q12, rs890049 (OR = 1.43, p = 1.4061026) on 2q35 and
rs7964864 (OR = 1.72, p = 6.7161026). The SNP rs890049 maps
to the tensin 1 (TNS1) locus encoding a protein involved in the
remodeling of the extracellular matrix. An additional nearby SNP
(rs4674220) in TNS1 showed p-value of 5.6661025 (OR = 1.35).
Interestingly, rs9349379 on 6p24, located in the gene encoding the
protein phosphatase 1 and actin regulator 1 (PHACTR1),
previously associated with early-onset MI[14–16], showed a p-
value of 1.5761025 (OR = 1.37). None of the SNPs in other
genomic regions previously associated with cardiovascular disease
showed similarly strong association with the degree of coronary
stenosis in our analysis [26].
Figure 2. Quantile-Quantile plot of the GWAS results. In this plot, each dot corresponds to a SNP tested for association where the observed –
log10 p values, shown by vertical axis, were plotted by the expected –log10 p values under the null hypothesis. Upper right dots with higher observed
significance than expected represent candidate variants for association with the phenotype tested (CAD category 1, control subjects; CAD category 2,
patients with #50% stenosis in any coronary artery; CAD category 3, patients with .50% stenosis in any of the coronary arteries). The genomic
control ratio (l) was 1.033, indicating the lack of strong effect of systematic error such as population stratification.
doi:10.1371/journal.pone.0038663.g002
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2. Replication Results
In order to confirm the association, a selection of 20 SNPs were
genotyped for replication with the Sequenom technology in the
entire cohort (n = 4,496). Concordance for genotypes between the
Illumina GWAS and the Sequenom data was .99% for all SNPs.
With the notable exception of SNPs in the PHACTR1 locus, none
of the other SNPs showed any improvement of the results in the
meta-analysis (Table 2). The SNP rs9349379 (Figure 3) showed
strong association in the replication phase (OR = 1.31,
p = 8.8561026), and its significance was improved in the meta-
analysis (OR = 1.34, p = 8.02610210). Another variant in
PHACTR1, rs12526453, which major allele C was previously
reported to be associated with increased risk (OR = 1.15) of early-
onset MI [15,16], was not in the exploratory genome-wide
BeadChip, but part of our replication effort (OR = 0.82,
p = 8.961024 for the minor allele G). Interestingly, our at-risk
allele G of rs9349379 (freq = 0.39 in the replication cohort)
occurred in the background of the common at-risk allele C of
rs12526453 (freq = 0.62 in the replication cohort) showing strong
Linkage Disequilibrium in our replication cohort at the haplotype
level only (D’ = 0.98, r2 = 0.37). Testing for independence between
these 2 signals with a multilocus analysis, we validated that our
new variant rs9349379 explained most of the association observed
in rs12526453; the size of its effect dropping from OR = 1.22 to
OR = 1.05. Most importantly, the SNP rs9349379 still showed
strong association with degree of stenosis independent of MI status
(OR = 1.34, p = 2.9461029). The respective significance of SNPs
in the PHACTR1 locus was further elucidated in the context of
regional recombination and LD (Figure 3) [27].
The SNPs were also tested for stenosis association with each of
the four main coronary arteries. Sorted by arteries, rs9349379 in
PHACTR1 most strongly impacted LAD, with an odds ratio of
1.33 (95%CI = 1.22–1.44, p = 6.04610212), followed by RCA and
LCx (Table 3).
Discussion
Here we report the first genome-wide scan for genetic
susceptibility to variable degrees of coronary artery stenosis in a
Middle East population. We demonstrate strong association with
variants in the PHACTR1 gene that was previously implicated in
early-onset MI [14–16]. GWA studies conducted in ethnically
distinct and geographically distant populations with varying
dietary habits, environmental exposures and differing cultures
provide useful comparisons yielding knowledge about the contri-
bution of specific genetic variants to increasingly prevalent diseases
worldwide [16,28,29]. The design methodologies followed in these
studies often display distinctive inclusion criteria and a variety of
parameters have to be taken into account to carry out the
necessary comparative analysis and interpretation. Variability in
study enrollment, such as family-based, cohort, and case-control
comparison strategies, as well as the use of different inclusion and
exclusion criteria, with variations applied even between screening
and validation stages of individual studies, all impact risk estimates.
Most importantly, CAD outcomes are classified by varying
standards. While some use coronary angiography to firmly verify
the disease status, others consider healthy individuals from the
general population as controls [16,28,29]. One of the strengths of
our study lies in the phenotypic characterization that is based on
stringent case-control definition criteria, whereby the percent of
stenosis in all four coronary arteries was determined based on
angiographic visualization. This study design excluded all asymp-
tomatic individuals with angiographic CAD from the control
Figure 3. Map around the PHACTR1 locus on chromosome 6 showing strong evidence of association with coronary artery stenosis.
The upper vertical bars correspond to the location of all markers tested from the SNP array chip in the area. The X-axis indicates the chromosomal
position in base-pairs on chromosome 6. Recombination rate is presented as a continuous blue line, while individual markers are represented by a
circle filled with a color corresponding to the extent of LD with the key marker rs9349379 (in red) from dark blue (r2 = 0) to red (r2 = 1). Grey filled
circles refer to SNPs with no LD information. The lower part represents the location of the genes with corresponding exons and the direction of
transcription indicated by arrows. The figure was generated with LocusZoom using CEU from HapMap release 22 as reference.
doi:10.1371/journal.pone.0038663.g003
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group and therefore minimized misclassification issues that may
arise when using unscreened control samples.
The meta-analysis of the exploratory and the replication sets
showed strong and genome-wide significant evidence for associ-
ation of SNP rs9349379 in PHACTR1 with arterial stenosis in all
arteries. Variants in PHACTR1 were originally associated with
early-onset MI in a study published by the MI Genetics
consortium [14–16]. The most significant SNP in these studies,
rs12526453 [15,16], was not part of our discovery, but showed
association in the replication set. However, its effect dropped after
taking into account the variant rs9349379 that appears on the
same background haplotype (D’ = 0.98, r2 = 0.37). Our results
confirm recent data [14] that suggests that rs9349379 may be a
better marker for the association than rs12526453. The role of
PHACTR1 in the pathophysiolgy of cardiovascular disease
remains to be elucidated. PHACTR1 is a regulator of protein
phosphatase 1 (PP1), an enzyme that regulates endothelial nitric
oxide [30], an important modulator of cardiovascular disease [31].
Furthermore, PP1 activity was shown to be elevated in patients
with end-stage heart failure [32].
In accordance with two recent publications [14,16], our results
confirm that PHACTR1 variants are associated with degree of
stenosis independent of MI. Indeed, when specific major vessels
were used as a stand-alone outcome variable, the association was
highest with the left anterior descending artery (LAD; OR = 1.33,
p = 6.04610212) and lowest with the left main artery (LMCA;
OR = 1.14, p = 2.7561022) (Table 3). The association was
significantly increased proportionate to number of vessels with
stenosis, reaching p = 7.27610210 when stenosis was present in all
4 vessels (data not shown). Since stenosis in the coronary arteries is
a major risk factor for MI, variants in PHACTR1 may at least in
part contribute to MI risk through an involvement in the
formation of stenosis in the cardiac vessels independently of a
role in Ca2+ homeostasis of the heart.
The association with rs9349379 remained significant after
adjustment for gender, hypertension, dyslipidemia, and diabetes
suggesting that these risk factors are not major contributors to the
observed association (data not shown). This variant remains
significant across different structured populations with diverse
dietary and genetic profiles, which demonstrates its strong genetic
component in the disease.
It is noteworthy that our GWAS did not show strong evidence
for association with degree of stenosis with other previously
identified gene variants for CAD. In part this may be due to
sample size. The number of individuals with no stenosis was
relatively modest in our study. Another factor may be that the
control group was somewhat younger on a whole and it cannot be
ruled out that some of these individuals may indeed develop
atherosclerosis in the future. These factors may have influenced
our power to detect associations. Some of the previously reported
SNPs are not present and are not well tagged by other markers on
the Illumina array used in this study. Also the role of the previously
Table 3. Results of the cumulative logit analyses for the most significant SNPs in the combined exploratory and replication phases
sorted by the level of significance using specific vessel stenosis as outcome variables.
LMCA
(n=403)
LAD
(n=366)
LCx
(n =64)
RCA
(n=473)
SNP
Candidate
gene
Effect
allele
Other
allele OR 95%CI p OR 95%CI p OR 95%CI p OR 95%CI p
rs9349379 PHACTR1 G A 1.14 1.01–1.28 2.75E-02 1.327 1.22–1.44 6.04E-12 1.187 1.10–1.29 2.89E-05 1.23 1.14–1.33 4.38E-07
rs2327620 PHACTR1 A G 0.903 0.81–1.01 8.29E-02 0.803 0.74–0.87 4.98E-08 0.864 0.80–0.93 2.39E-04 0.864 0.80–0.93 2.48E-04
rs206184 MACC1-ITGB8 C T 1.082 0.96–1.22 1.86E-01 1.152 1.06–1.25 5.87E-04 1.125 1.04–1.22 4.12E-03 1.085 1.00–1.18 4.59E-02
rs4674220 TNS1 G A 1.093 0.97–1.23 1.42E-01 1.103 1.02–1.20 2.07E-02 1.166 1.07–1.27 2.77E-04 1.133 1.04–1.23 3.16E-03
rs11186734 T C 0.769 0.60–0.98 3.26E-02 0.764 0.66–0.89 4.46E-04 0.883 0.76–1.03 1.07E-01 0.767 0.66–0.89 6.65E-04
rs7964864 KCNC2 C A 1.129 0.95–1.34 1.70E-01 1.077 0.95–1.22 2.46E-01 1.163 1.03–1.32 1.73E-02 1.114 0.98–1.26 8.92E-02
rs890049 TNS1 T C 1.036 0.92–1.17 5.56E-01 1.126 1.04–1.22 4.28E-03 1.128 1.04–1.22 3.47E-03 1.113 1.03–1.21 9.24E-03
rs6974002 MACC1-ITGB8 G A 0.994 0.88–1.13 9.23E-01 1.173 1.08–1.28 3.29E-04 1.071 0.98–1.17 1.20E-01 1.04 0.95–1.13 3.71E-01
rs13006511 GCC2-LIMS1 C T 0.939 0.79–1.11 4.66E-01 0.898 0.8–1.00 6.08E-02 0.957 0.85–1.07 4.52E-01 0.928 0.83–1.04 1.96E-01
rs4708388 SMOC2-THBS2 A G 0.787 0.65–0.95 1.39E-02 0.874 0.77–0.99 2.92E-02 0.833 0.74–0.94 3.51E-03 0.859 0.76–0.97 1.44E-02
rs6455455 SMOC2-THBS2 C T 0.899 0.75–1.08 2.64E-01 0.866 0.77–0.98 2.26E-02 0.841 0.74–0.95 6.89E-03 0.848 0.75–0.96 9.40E-03
rs2577625 GCC2-LIMS1 T C 1.06 0.95–1.19 3.10E-01 0.944 0.87–1.02 1.48E-01 0.934 0.86–1.01 8.76E-02 0.898 0.83–0.97 6.87E-03
rs16891359 Histone cluster C T 1.099 0.85–1.41 4.63E-01 1.094 0.91–1.31 3.29E-01 1.159 0.97–1.39 1.08E-01 1.162 0.97–1.39 9.58E-02
rs7919192 C T 0.976 0.87–1.10 6.85E-01 0.919 0.85–1.00 4.12E-02 0.944 0.87–1.02 1.64E-01 0.917 0.85–0.99 3.49E-02
rs1543121 NTM T G 1.196 1.02–1.41 3.22E-02 1.032 0.92–1.16 6.04E-01 1.053 0.93–1.19 3.94E-01 1.129 1.00–1.27 4.39E-02
rs7294453 KCNC2 G T 1.093 0.90–1.33 3.82E-01 1.048 0.91–1.21 5.26E-01 1.065 0.92–1.23 3.84E-01 1.014 0.88–1.17 8.45E-01
rs4936137 NTM A G 1.16 0.98–1.37 7.90E-02 1.023 0.91–1.15 7.03E-01 1.056 0.94–1.19 3.67E-01 1.126 1.00–1.27 4.95E-02
rs9805437 FGF14 G A 1.145 0.97–1.35 1.00E-01 1.034 0.92–1.16 5.69E-01 1.107 0.99–1.24 8.30E-02 1.077 0.96–1.21 1.98E-01
rs4535467 CDH6 A G 0.963 0.80–1.16 6.86E-01 1.208 1.06–1.37 3.61E-03 1 0.88–1.13 9.96E-01 0.997 0.88–1.13 9.60E-01
rs7995765 FGF14 T C 1.105 0.93–1.31 2.52E-01 1.059 0.94–1.20 3.53E-01 1.2 1.06–1.35 2.98E-03 1.072 0.95–1.21 2.59E-01
The number of patients with site specific stenosis is marked next to the vessel type. Patients in each stenosis site category were compared to the n= 642 controls
available.
Alleles follow forward strand of NCBI36 reference genome. LMCA: left main artery; LAD: left anterior descending artery; LCx: left circumflex artery; RCA: right coronary
artery.
doi:10.1371/journal.pone.0038663.t003
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associated SNPs may differ among populations with different
lifestyle patterns, or their distribution is such that significant
associations cannot be assessed with equal power in the different
populations studied.
Although they did not reach the same level of significance,
many of the formerly reported variants showed nominally
significant p values in the same direction as those reported [26].
The 9p21 locus that was shown to be associated with coronary
heart disease in more than one GWAS [16,28,33], in particular
variant rs4977574, did not show genome-wide significance for
association with CAD (PCA adjusted p = 0.0107) or MI
(p = 0.00448) in our study population [28]. Interestingly, a
candidate gene approach was used to test association of candidate
SNPs with CAD and/or MI in genotypic and allelic association
models using logistic regression [26]. Results showed that the
variant rs4977574 in CDKN2A-CDKN2B in the 9p21 locus was
significantly associated with MI (OR = 1.33, p = 0.0086) in the
Lebanese population. Association was detected after adjustment
for confounding risk factors.
A parallel approach was conducted on a list of 20,225 variants
in 88 previously published genes for association in our Lebanese
cohort. The study was based on our genome-wide genotype data
set, with imputation across the whole genome to CEU HapMap
population as a reference. This approach identified a significant
association of two new loci with CAD (CDKAL1 and PTPRD), in
addition to the CXCL12 locus. Further, we identified ST6GAL1 as
having a protective effect against CAD/MI [26].
Our results contribute to ongoing efforts aiming at identifying
genes associated with the multifaceted CAD and can provide
important perspectives in disease diagnosis as well as new avenues
for drug discovery.
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